Gapping up
In reaction to strong earnings/guidance:
- COTY +14.4%, AVYA +13.1%, CAH +9.2%, ORA +9.1%, UNVR +9%, AN +8.8%, CEVA +7.7%, BLUE +6.9%, GIS +1.9%, ICPT +1.7%, GOGO +1.4%, TLYS +0.8%
M&A news:
- AMC +60.2% (Amazon (AMZN) potentially in discussions to acquire AMC, according to Daily Mail )
Other news:
- MYOK +71.9% (reports Phase 3 EXPLORER clinical trial of Mavacamten met all primary and all secondary endpoints)
- QDEL +16.6% (receives Emergency Authorization from the FDA for rapid antigen COVID-19 diagnostic assay)
- PLX +11.9% (reports Phase III BRIDGE open-label, switch-over clinical trial met main objectives for safety and efficacy)
- MYGN +6.7% (receives FDA approval for myChoice CDx as companion diagnostic for Lynparza)
Analyst comments:
- DBD +3.7% (upgraded to Neutral from Underweight at JP Morgan)
- COLD +1.4% (upgraded to Buy from Neutral at BofA/Merrill)
- SABR +1.4% (upgraded to Outperform from Mkt Perform at Bernstein)
- CVA +1.1% (upgraded to Hold from Sell at Stifel)